These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24525428)

  • 41. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
    Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ
    Prostate; 2018 Mar; 78(4):308-317. PubMed ID: 29314097
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells.
    Tyagi A; Singh RP; Agarwal C; Siriwardana S; Sclafani RA; Agarwal R
    Carcinogenesis; 2005 Nov; 26(11):1978-87. PubMed ID: 15975956
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
    Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
    Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pectenotoxin-2 induces G2/M phase cell cycle arrest in human breast cancer cells via ATM and Chk1/2-mediated phosphorylation of cdc25C.
    Moon DO; Kim MO; Nam TJ; Kim SK; Choi YH; Kim GY
    Oncol Rep; 2010 Jul; 24(1):271-6. PubMed ID: 20514472
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide.
    Higuchi F; Fink AL; Kiyokawa J; Miller JJ; Koerner MVA; Cahill DP; Wakimoto H
    Mol Cancer Ther; 2018 Dec; 17(12):2551-2563. PubMed ID: 30217967
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells.
    Tyagi S; Bhui K; Singh R; Singh M; Raisuddin S; Shukla Y
    Biochem Pharmacol; 2010 Nov; 80(9):1326-34. PubMed ID: 20655883
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells.
    Puhr M; Hoefer J; Neuwirt H; Eder IE; Kern J; Schäfer G; Geley S; Heidegger I; Klocker H; Culig Z
    Oncotarget; 2014 Dec; 5(23):12043-56. PubMed ID: 25474038
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy.
    Lin JZ; Wang WW; Hu TT; Zhu GY; Li LN; Zhang CY; Xu Z; Yu HB; Wu HF; Zhu JG
    Cancer Lett; 2020 Jan; 469():481-489. PubMed ID: 31738958
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Chk1-Cdc25C regulation is involved in sensitizing A253 cells to a novel topoisomerase I inhibitor BNP1350 by bax gene transfer.
    Yin M; Hapke G; Guo B; Azrak RG; Frank C; Rustum YM
    Oncogene; 2001 Aug; 20(38):5249-57. PubMed ID: 11536038
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance.
    Zhang M; Osisami M; Dai J; Keller JM; Escara-Wilke J; Mizokami A; Keller ET
    Mol Cancer Res; 2017 Apr; 15(4):457-466. PubMed ID: 28087740
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic relevance of the protein phosphatase 2A in cancer.
    Cunningham CE; Li S; Vizeacoumar FS; Bhanumathy KK; Lee JS; Parameswaran S; Furber L; Abuhussein O; Paul JM; McDonald M; Templeton SD; Shukla H; El Zawily AM; Boyd F; Alli N; Mousseau DD; Geyer R; Bonham K; Anderson DH; Yan J; Yu-Lee LY; Weaver BA; Uppalapati M; Ruppin E; Sablina A; Freywald A; Vizeacoumar FJ
    Oncotarget; 2016 Sep; 7(38):61544-61561. PubMed ID: 27557495
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel.
    Yang Z; Chen JS; Wen JK; Gao HT; Zheng B; Qu CB; Liu KL; Zhang ML; Gu JF; Li JD; Zhang YP; Li W; Wang XL; Zhang Y
    J Exp Clin Cancer Res; 2017 Dec; 36(1):178. PubMed ID: 29216925
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fez1/Lzts1 absence impairs Cdk1/Cdc25C interaction during mitosis and predisposes mice to cancer development.
    Vecchione A; Baldassarre G; Ishii H; Nicoloso MS; Belletti B; Petrocca F; Zanesi N; Fong LY; Battista S; Guarnieri D; Baffa R; Alder H; Farber JL; Donovan PJ; Croce CM
    Cancer Cell; 2007 Mar; 11(3):275-89. PubMed ID: 17349584
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.
    Saatci Ö; Borgoni S; Akbulut Ö; Durmuş S; Raza U; Eyüpoğlu E; Alkan C; Akyol A; Kütük Ö; Wiemann S; Şahin Ö
    Oncogene; 2018 Apr; 37(17):2251-2269. PubMed ID: 29391599
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.
    Qian DZ; Rademacher BL; Pittsenbarger J; Huang CY; Myrthue A; Higano CS; Garzotto M; Nelson PS; Beer TM
    Prostate; 2010 Mar; 70(4):433-42. PubMed ID: 19866475
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer.
    Lee BY; Hochgräfe F; Lin HM; Castillo L; Wu J; Raftery MJ; Martin Shreeve S; Horvath LG; Daly RJ
    Mol Cancer Ther; 2014 Jan; 13(1):190-201. PubMed ID: 24194567
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function.
    Cogswell JP; Brown CE; Bisi JE; Neill SD
    Cell Growth Differ; 2000 Dec; 11(12):615-23. PubMed ID: 11149596
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chemogenetic profiling identifies RAD17 as synthetically lethal with checkpoint kinase inhibition.
    Shen JP; Srivas R; Gross A; Li J; Jaehnig EJ; Sun SM; Bojorquez-Gomez A; Licon K; Sivaganesh V; Xu JL; Klepper K; Yeerna H; Pekin D; Qiu CP; van Attikum H; Sobol RW; Ideker T
    Oncotarget; 2015 Nov; 6(34):35755-69. PubMed ID: 26437225
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
    van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.